CoChat

Comparison of tumor-informed and tumor-naïve sequencing assays for ctDNA detection in breast cancer

Open access

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

Abstract

Analysis of circulating tumor DNA (ctDNA) to monitor cancer dynamics and detect minimal residual disease has been an area of increasing interest. Multiple methods have been proposed but few studies have compared the performance of different approaches. Here, we compare detection of ctDNA in serial plasma samples from patients with breast cancer using different tumor-informed and tumor-naïve assays designed to detect structural variants (SVs), single nucleotide variants (SNVs), and/or somatic copy-number aberrations, by multiplex PCR, hybrid capture, and different depths of whole-genome sequencing. Our results demonstrate that the ctDNA dynamics and allele fractions (AFs) were highly concordant when analyzing the same patient samples using different assays. Tumor-informed assays showed the highest sensitivity for detection of ctDNA at low concentrations. Hybrid capture sequencing targeting between 1,347 and 7,491 tumor-identified mutations at high depth was the most sensitive assay, detecting ctDNA down to an AF of 0.00024% (2.4 parts per million, ppm). Multiplex PCR targeting 21-47 tumor-identified SVs per patient detected ctDNA down to 0.00047% AF (4.7 ppm) and has potential as a clinical assay.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.202216505

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Overview of the study design. Longitudinal plasma samples (n = 54) from seven breast cancer patients, with either early-stage (n = 4) or late-stage (n = 3) disease, were analyzed using different ctDNA assays. As controls, plasma samples (n = 19) from healthy donors were analyzed. Whole genome sequencing (WGS) of tumor and matched buffy coat DNA was first performed to identify patient-specific structural variants (SVs) and single nucleotide variants (SNVs). These were used to define tumor-informed ctDNA assays including targeted sequencing and whole genome sequencing (WGS) to different depths of sequencing. Targeted sequencing to evaluate SVs and SNVs (SV-multiplex PCR, SV-hybrid capture and SNV-hybrid capture) were performed in all 54 patient plasma samples. WGS at various depths was performed in a subset of 21 samples that were then downsampled to 600M reads (modWGS, mean coverage depth 20x) prior to further analyzes; these included 12 samples with deep sequencing (deepWGS, mean coverage depth 399x) analyzed before and after downsampling. As a tumor-informed approach, SVs and SNVs were analyzed in the modWGS (SV-modWGS and SNV-modWGS) and the deepWGS assays (SV-deepWGS and SNV-deepWGS). Somatic copy-number aberrations (SCNAs) were evaluated using WGS as a tumor-naïve approach (not requiring prior knowledge of the tumor) by shallow WGS (SCNA-sWGS, mean coverage depth 1.2x, 54 samples), modWGS (SCNA-modWGS), and deepWGS (SCNA-deepWGS, 12 samples).
Figure 1 Overview of the study design. Longitudinal plasma samples (n = 54) from seven breast cancer patients, with either early-stage (n = 4) or late-stage (n = 3) disease, were analyzed using different ctDNA assays. As controls, plasma samples (n = 19) from healthy donors were analyzed. Whole genome sequencing (WGS) of tumor and matched buffy coat DNA was first performed to identify patient-specific structural variants (SVs) and single nucleotide variants (SNVs). These were used to define tumor-informed ctDNA assays including targeted sequencing and whole genome sequencing (WGS) to different depths of sequencing. Targeted sequencing to evaluate SVs and SNVs (SV-multiplex PCR, SV-hybrid capture and SNV-hybrid capture) were performed in all 54 patient plasma samples. WGS at various depths was performed in a subset of 21 samples that were then downsampled to 600M reads (modWGS, mean coverage depth 20x) prior to further analyzes; these included 12 samples with deep sequencing (deepWGS, mean coverage depth 399x) analyzed before and after downsampling. As a tumor-informed approach, SVs and SNVs were analyzed in the modWGS (SV-modWGS and SNV-modWGS) and the deepWGS assays (SV-deepWGS and SNV-deepWGS). Somatic copy-number aberrations (SCNAs) were evaluated using WGS as a tumor-naïve approach (not requiring prior knowledge of the tumor) by shallow WGS (SCNA-sWGS, mean coverage depth 1.2x, 54 samples), modWGS (SCNA-modWGS), and deepWGS (SCNA-deepWGS, 12 samples).CC BY · PubMed Central
Figure 2 Relationship between observed and expected allele fractions (AFs) in tumor dilution series with SV-multiplex PCR. Numbers in brackets indicate the number of SVs (structural variants) targeted by SV-multiplex PCR in each patient. Tumor dilutions ranged 0.0004% - 10% AF. Solid lines represent the linear regression of the dilution series. The vertical and horizontal dashed lines represent the theoretical limit of detection of each assay based on the number of analyzed SVs and input cell-free DNA copies. The diagonal dotted line represents the unit line. The solid black line shows the linear regression fit. The p-values of the slope parameter Wald t-tests as well as the linear model fit R squared estimates are also indicated.
Figure 2 Relationship between observed and expected allele fractions (AFs) in tumor dilution series with SV-multiplex PCR. Numbers in brackets indicate the number of SVs (structural variants) targeted by SV-multiplex PCR in each patient. Tumor dilutions ranged 0.0004% - 10% AF. Solid lines represent the linear regression of the dilution series. The vertical and horizontal dashed lines represent the theoretical limit of detection of each assay based on the number of analyzed SVs and input cell-free DNA copies. The diagonal dotted line represents the unit line. The solid black line shows the linear regression fit. The p-values of the slope parameter Wald t-tests as well as the linear model fit R squared estimates are also indicated.CC BY · PubMed Central
Figure 3 ctDNA detection and fractions using the different ctDNA assays. ctDNA fractions are plotted as an allele fraction for SV/SNV assays and as tumor fraction for SCNA assays. (A-C) Targeted assays and (H) shallow WGS (sWGS, mean depth 1.2x) were performed in all plasma samples (n = 54), (D, F, I) moderately deep WGS (modWGS, mean depth 20x) in a subset of 21 plasma samples and (E, G, J) deep WGS (deepWGS, mean depth 399x) in a subset of 12 samples (included also in modWGS). Plots (A-J) show the ctDNA fraction from each individual assay. A) SV-multiplex PCR assay: all detected plasma samples were assayed using up to 4,500 cell-free DNA amplifiable copies except patient P-IV-03 plasma timepoint 3, which was detected after increasing the input amount to 27,000 cell-free DNA copies; B) SV-hybrid capture assay; C) SNV-hybrid capture assay: patient P-IA-02 plasma timepoint 4 and timepoint 5 were detected only after applying INVAR size-weighting feature D) SV-modWGS assay; E) SV-deepWGS; F) SNV-modWGS: patient P-IA-02 plasma timepoint 4 was detected only after applying INVAR size-weighting feature; G) SNV-deepWGS; H) SCNA-sWGS assay: patient P-IV-01 plasma timepoint 1 was detected only after in silico 90-150bp size-selection; I) SCNA-modWGS assay: patient P-IV-02 plasma timepoint 1 was detected only after in silico 90-150bp size-selection; J) SCNA-deepWGS.
Figure 3 ctDNA detection and fractions using the different ctDNA assays. ctDNA fractions are plotted as an allele fraction for SV/SNV assays and as tumor fraction for SCNA assays. (A-C) Targeted assays and (H) shallow WGS (sWGS, mean depth 1.2x) were performed in all plasma samples (n = 54), (D, F, I) moderately deep WGS (modWGS, mean depth 20x) in a subset of 21 plasma samples and (E, G, J) deep WGS (deepWGS, mean depth 399x) in a subset of 12 samples (included also in modWGS). Plots (A-J) show the ctDNA fraction from each individual assay. A) SV-multiplex PCR assay: all detected plasma samples were assayed using up to 4,500 cell-free DNA amplifiable copies except patient P-IV-03 plasma timepoint 3, which was detected after increasing the input amount to 27,000 cell-free DNA copies; B) SV-hybrid capture assay; C) SNV-hybrid capture assay: patient P-IA-02 plasma timepoint 4 and timepoint 5 were detected only after applying INVAR size-weighting feature D) SV-modWGS assay; E) SV-deepWGS; F) SNV-modWGS: patient P-IA-02 plasma timepoint 4 was detected only after applying INVAR size-weighting feature; G) SNV-deepWGS; H) SCNA-sWGS assay: patient P-IV-01 plasma timepoint 1 was detected only after in silico 90-150bp size-selection; I) SCNA-modWGS assay: patient P-IV-02 plasma timepoint 1 was detected only after in silico 90-150bp size-selection; J) SCNA-deepWGS.CC BY · PubMed Central
Figure 4 SCNA signal enrichment after in silico 90-150bp size-selection in patients P-IV-01 and P-IV-02. A-D) Patient P-IV-01: When analyzed with SCNA-sWGS, (A) P-IV-01 plasma timepoint 1 show a flat profile before in silico size-selection and a tumor fraction of 2.3%, i.e. below the ichorCNA recommended cut-off of 3%, while (B) after 90-150bp size selection copy number changes can be observed. These copy numbers match those observed (C) in tumor and are not present in (D) matched buffy coat. E-H) P-IV-02: E) When analyzed with SCNA-modWGS, P-IV-02 plasma timepoint 1 has a tumor fraction below the ichorCNA recommended cut-off of 3% (tumor fraction of 2.6%) and is, therefore, classified as undetected even though small copy-number changes can be observed. F) Following in silico size selection, those changes become more apparent. The copy number aberrations match those observed (G) in tumor and are not present in (H) matched buffy coat.
Figure 4 SCNA signal enrichment after in silico 90-150bp size-selection in patients P-IV-01 and P-IV-02. A-D) Patient P-IV-01: When analyzed with SCNA-sWGS, (A) P-IV-01 plasma timepoint 1 show a flat profile before in silico size-selection and a tumor fraction of 2.3%, i.e. below the ichorCNA recommended cut-off of 3%, while (B) after 90-150bp size selection copy number changes can be observed. These copy numbers match those observed (C) in tumor and are not present in (D) matched buffy coat. E-H) P-IV-02: E) When analyzed with SCNA-modWGS, P-IV-02 plasma timepoint 1 has a tumor fraction below the ichorCNA recommended cut-off of 3% (tumor fraction of 2.6%) and is, therefore, classified as undetected even though small copy-number changes can be observed. F) Following in silico size selection, those changes become more apparent. The copy number aberrations match those observed (G) in tumor and are not present in (H) matched buffy coat.CC BY · PubMed Central
Figure 5 Correlation of the ctDNA fractions calculated with all assays performed. Allele fractions plotted for SV/SNV assays, tumor fractions for SCNA assays. The SNV-hybrid capture assay was used as reference (x axis), with the other assays plotted on a common y axis. Colored lines correspond to the linear regression fits per assay. The Pearson's correlation coefficient estimates and p-values of the corresponding tests of associations are also indicated. Spearman rank correlations led to the same conclusions (range R=0.98 to R=1.00).
Figure 5 Correlation of the ctDNA fractions calculated with all assays performed. Allele fractions plotted for SV/SNV assays, tumor fractions for SCNA assays. The SNV-hybrid capture assay was used as reference (x axis), with the other assays plotted on a common y axis. Colored lines correspond to the linear regression fits per assay. The Pearson's correlation coefficient estimates and p-values of the corresponding tests of associations are also indicated. Spearman rank correlations led to the same conclusions (range R=0.98 to R=1.00).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 3

  1. Illumina Press Release Illumina Unveils Revolutionary NovaSeq X Series to Rapidly Accelerate Genomic Discoveries and Improve Human Health 2022 https://investor.illumina.com/news/press-release-details/2022/Illumina-Unveils-Revolutionary-NovaSeq-X-Series-to-Rapidly-Accelerate-Genomic-Discoveries-and-Improve-Human-Health/default.aspx
  2. Kurtz DM Soo J Co Ting Keh L Alig S Chabon JJ Sworder BJ Schultz A Jin MC Scherer F Garofalo A Enhanced detection of minimal residual disease by targeted sequencing of phased variants incirculating tumor DNA Nat Biotechnol 2021 b 39 1537 1547 34294911 PMC8678141 · DOI · Paper page
  3. Li Heng Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM arXiv:13033997v2 q-bioGN

Cited by

See all 76

Metadata

Authors
Santonja, A., Cooper, W. N., Eldridge, M. D., Edwards, P. A. W., Morris, J. A., Edwards, A. R., Zhao, H., Heider, K., Couturier, D., Vijayaraghavan, A., Mennea, P., Ditter, E., Smith, C. G., Boursnell, C., Manzano García, R., Rueda, O. M., Beddowes, E., Biggs, H., Sammut, S., Rosenfeld, N., Caldas, C., Abraham, J. E., & Gale, D.
Affiliations
University of Cambridge (GB)
Corresponding author
  • Abraham, Jean E
  • Gale, Davina
Venue
EMBO Molecular Medicine
Published
2023-05-10
Volume
15
Issue
6
Pages
e16505-e16505
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W4376121423
Cited by
66
References
61
Citations by year
2026: 16 · 2025: 36 · 2024: 12 · 2023: 2
FWCI
8.36
Type
journal article
Language
en
Open access
Licence
Locations
  • EMBO Molecular Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Addenbrooke's Charitable Trust, Cambridge University Hospitals (ACT 9800)
  • AstraZeneca (A093777)
  • Cancer Research UK (C507/A27657, CRUKE/14/048, C36857/A27548, C1287/A26886, C17918/A28870, EDDCPT\100013)
  • EC | FP7 | Ideas | FP7 Ideas: European Research Council (337905)
  • Mark Foundation For Cancer Research (C9685/A25177)
  • NIHR | NIHR Cambridge Biomedical Research Centre (BRC‐1215‐20014)
  • University of Cambridge | Cancer Research UK Cambridge Institute, University of Cambridge (A20240, C9545/A29580)
  • Wellcome Trust (106566/Z/14/Z)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Prenatal Screening and Diagnostics
Keywords
circulating tumor DNA, breast cancer, liquid biopsy, hybrid capture sequencing, multiplex PCR, structural variants, single nucleotide variants, somatic copy number alterations, minimal residual disease, allele fraction, assay sensitivity comparison
MeSH terms
Circulating Tumor DNA, Breast Neoplasms, Female, Humans, Mutation, Biomarkers, Tumor, High-Throughput Nucleotide Sequencing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.